Drug Trial Radar · NCT04785820
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Jun 25, 2021
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC) refractory or intolerant to fluoropyrimidine- or taxane- and platinum-based regimen. Following approval of the protocol amendment version 3, recruitment into the lomvastomig arm has been stopped. The decision to stop recruitment for lomvastomig was based on strategic considerations and not based on emerging safety and/or efficacy data. The benefit/risk assessment for lomvastomig remains unchanged. The study was planned to enroll participants randomized in a 1:1:1 ratio to receive lomvastomig, tobemstomig, or nivolumab. With version 3 of the protocol, recruitment into the lomvastomig arm has stopped, and moving forward, participants will be randomized in a 1:1 ratio to receive either tobemstomig or nivolumab.
Conditions
- Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Interventions
LomvastomigDrug
2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
TobemstomigDrug
2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
NivolumabDrug
240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization to death (up to approximately 38.7 months)
Locations
52 sites in 18 countries. Site status is shown where the registry gives one.
Inst. Alexander Fleming
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Masaryk?v onkologický ústav
Brno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Rigshospitalet
København Ø, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, Denmark
Hopital Claude Huriez
Lille, France
Centre Leon Berard
Lyon, France
Hopital Timone Adultes
Marseille, France
Institut régional du Cancer Montpellier
Montpellier, France
APHP - Hopital Saint Antoine
Paris, France
ICO Rene Gauducheau
Saint-Herblain, France
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
Szolnok, Hungary
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, Italy
Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della
Udine, Friuli Venezia Giulia, Italy
IRCCS Istituto Oncologico Veneto (IOV)
Padova, Veneto, Italy
International Cancer Institute (ICI)
Eldoret, Kenya
The Aga Khan University-Kenya.
Nairobi, Kenya
Centrum Onkologii w Bydgoszczy
Bydgoszcz, Poland
Szpital Morski im. PCK
Gdynia, Poland
Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II
Krakow, Poland
NIO im Marii Sklodowskiej-Curie
Warsaw, Poland
Bashkirian Republican Clinical Oncology Dispensary
Ufa, Bashkortostan Republic, Russia
First Moscow State Medical University n.a. I.M. Sechenov
Moscow, Moscow Oblast, Russia
MEDSI Clinical Hospital on Pyatnitsky Highway
Moscow, Moscow Oblast, Russia
Group of companies "Medci"
Moskva, Moscow Oblast, Russia
National Cancer Centre
Singapore, Singapore
Curie Oncology
Singapore, Singapore
Chonnam National University Hwasun Hospital
Jeollanam-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Clínic i Provincial
Barcelona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Changhua Christian Hospital
Chang-hua, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
National Taiwan University Hospital
Zhongzheng Dist., Taiwan
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.